Inflazome closes US$17m Series A financing round from Novartis Venture Fund and Fountain Healthcare Partners to develop treatments for chronic inflammatory diseases | Business Wire

DUBLIN–(BUSINESS WIRE)–Inflazome (inflazome.com)

has successfully closed a Series A financing round for up to US$17/€15

million. Two leading life sciences venture capital firms, Novartis

Venture Funds and Fountain Healthcare Partners, co-led the financing.

Inflazome is developing inhibitors of the inflammasome, a compelling

biological target that regulates our innate immune response, now

associated with a wide variety of diseases. Following the closure of the

financing round, Florent Gros (Managing Director of Novartis Venture

Fund). Dr. Manus Rogan (Co-Founder and Managing Director at Fountain

Healthcare Partners) joined the Board of Directors.

Commenting on the launch of Inflazome, Dr. Matt Cooper, Co-Founder and

CEO of Inflazome, stated “Inflammasome activation is now implicated

in many diseases driven by chronic inflammation, from Parkinson’s to

Asthma. These conditions are often inadequately treated by current

therapies. We want to help people with debilitating diseases facing

limited or no treatment options.”

Successful Affiliate Marketing On The Internet

People often want to earn commissions by selling products or services, but do not own a company, or have their own products, or even have a website. This does not exclude them from making a decent living in the sales industry; they can become affiliate marketers. Countless thousands of domestic and foreign companies want independent help in promoting their merchandise, and contrary to popular belief, affiliate marketing is not a closed industry.
Becoming an affiliate marketer for someone else's product line is not a new fad. In fact, it has been a staple of the sales industry for centuries. In today's internet-based economy, old-fashioned word-of-mouth has a new meaning, because information exchange is not only lightning fast, it is available to just about everyone on the planet. The way companies conduct their everyday business, from testing out new products to keeping established customers, revolves around the 21st century version of getting the word out.
Basically, affiliate marketing in its contemporary dress is rather simple: an affiliate marketer seeks a company whose products or services are interesting and saleable, and then decides to help out with the promotion of that company's product. In return, the affiliate earns a share of the profit. For example, if Company "A" sells garden gnomes, they are probably advertised on the internet. Company "A" will have their own website, complete with product information about their garden gnomes, and customers can order by placing items in a shopping cart and proceeding to online checkout, paying with a credit or debit card. In addition, the company advertises on Google, Internet Explorer, or other search engines. An affiliate is allowed to participate in the same advertising game.
The independent affiliate will obtain a special destination URL code that is incorporated into all online text, video or banner ads. Customers who click on...

Prof. Luke O’Neill Co-Founder and CSO added, “Animal models and

clinical data suggests there is tremendous opportunity to stop the cycle

of chronic inflammation in a range of diseases. We believe that

targeting the inflammasome has tremendous potential for a wide range of

inflammatory diseases where current treatments are ineffective.”

Dr. Manus Rogan, Co-Founder and Managing Partner at Fountain Healthcare

Partners said “Considering the breadth and depth of possible

applications, the commercial potential for a successful small molecule

inhibitor of this key target is clearly in the billions of dollars

range.”

Florent Gros, Managing Director at Novartis Venture Fund said, “We

have searched extensively for inhibitors of the inflammasome. We're

very excited by Inflazome’s prospects. The company has outstanding

assets, expertise and capabilities.”

Inflazome

Utilizing the scientific expertise of our founders and advisors,

Fuchs North America Makes New Corporate Appointments

Baltimore, MD (PRWEB) December 22, 2011

Fuchs North America, a leading supplier of seasonings and taste solutions to the food manufacturing and foodservice industries, announces three corporate appointments at its headquarters location in Owings Mills in suburban Baltimore, MD.

Kenneth R. Wuestenfeld has joined Fuchs North America as Vice President of Sales & Business Development. In this position, Wuestenfeld will expand and further develop the company’s North American customer base, as well as identify new segment opportunities.

Wuestenfeld began his career in the food manufacturing industry in the early 1980s. Prior to joining Fuchs North America, he held several executive-level positions with ConAgra Foods – first as general manager for the Lamb Weston subsidiary where he managed two plants and a sales/marketing organization. Subsequently, he led sales and marketing efforts for the Gilroy Foods & Flavors ingredient division of ConAgra.

Wuestenfeld has also held sales and managerial positions at Sara Lee Bakery, PepsiCo and Nestlé. He has a BS degree in Marketing Management from the University of Arizona and an MBA degree in Marketing & Business Management from DePaul University in Chicago.

Felix Venezuela has joined Fuchs North America as Director of Operations. In this position, Venezuela will focus on enhancing the company’s production facilities to accommodate growth in existing product segments as well as expansion into new ones.

Venezuela has more than 25 years of experience in the food industry, working at Quaker Oats, Sara Lee and Massimo Zanetti Beverage. Prior to joining Fuchs North America, he was Plant Manager at Young Pecan/Hampton Farms in Las Cruces, NM, where he is credited with maximizing productivity and optimizing overall plant efficiencies for this large pecan processing and packaging facility.

Venezuela began his career in Human Resources, for which he credits his ability to manage, motivate and empower employees...

Inflazome is leading the way in developing orally available drugs to

address clinical unmet needs in inflammatory diseases by targeting the

inflammasome, which is now thought to drive many chronic inflammatory

conditions.

Headquartered in Dublin, Ireland, Inflazome was founded by leading

academics Prof. Matt Cooper, The University of Queensland (Australia)

and Prof. Luke O’Neill Trinity College Dublin (Ireland), following a

highly productive joint collaboration. Joining the founding management

team as VP of Business Development is experienced industry executive,

Dr. Jeremy Skillington, formally of Genentech. inflazome.com

Founding investors are Fountain Healthcare Partners (Dublin, Ireland)

and Novartis Venture Fund (Basel, Switzerland).

Fountain Healthcare Partners

Fountain Healthcare Partners is a life science focused venture capital

fund with €176 million ($200 million) under management. Within the life

science sector, specific areas of interest to Fountain include specialty

pharma, medical devices, biotechnology and diagnostics. The firm deploys

the majority of its capital in Europe, with the balance in the United

States. Fountain’s main office is in Dublin, Ireland, with a second

office in New York. fh-partners.com

The Novartis Venture Fund

The Novartis Venture Fund (NVF) manages over $700 million in committed

capital. NVF invests in companies that have the potential to change a

core therapeutic field or explore new business areas that'll be

critical to patient care. NVF’s primary interest is in the development

of novel therapeutics and platforms as well as medical devices,

diagnostics. Delivery systems. The Funds invest for financial

objectives at all stages. Prefers to invest in the early-stages of

company development. With investment professionals located in Basel,

Switzerland and Cambridge, MA the team has extensive experience in

pharmaceutical R&D and venture capital. nvfund.com